Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mirum Pharmaceuticals Inc MIRM

Healthcare Biotechnology
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development and commercialization of therapies for debilitating rare and orphan diseases. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal (chenodiol) tablets. Livmarli is an orally administered, minimally... see more

Recent & Breaking News (NDAQ:MIRM)

Mirum Pharmaceuticals Announces Commencement of Public Offering of Common Stock

Business Wire August 9, 2022

Mirum Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

Business Wire August 4, 2022

Mirum Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on August 4, 2022

Business Wire July 28, 2022

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire July 8, 2022

Mirum Pharmaceuticals Highlights Data Demonstrating Impact of LIVMARLI® (maralixibat) on Patients with Alagille Syndrome at European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Annual Meeting

Business Wire June 24, 2022

Mirum Pharmaceuticals Presents New Data at The International Liver Congress(TM) of the European Association for the Study of the Liver (EASL)

Business Wire June 24, 2022

Mirum Pharmaceuticals to Showcase LIVMARLI® (maralixibat) Data at EASL and ESPGHAN Annual Congresses

Business Wire June 13, 2022

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire June 10, 2022

Mirum Pharmaceuticals Appoints Saira Ramasastry to Board of Directors

Business Wire June 6, 2022

Mirum Pharmaceuticals Acquires Satiogen Pharmaceuticals

Business Wire May 23, 2022

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Business Wire May 18, 2022

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire May 10, 2022

Mirum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

Business Wire May 5, 2022

Mirum Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on May 5, 2022

Business Wire May 2, 2022

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire April 8, 2022

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire March 10, 2022

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update

Business Wire March 9, 2022

Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End Business Results for 2021 and Host Conference Call on March 9, 2022

Business Wire March 2, 2022

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire February 10, 2022

Mirum Pharmaceuticals to Present at SVB Leerink 11th Annual Global Healthcare Conference

Business Wire February 9, 2022